作为AML治疗的抗癌剂的Fms类氨酸激酶3抑制剂的发展
Chenchen Ma1,2,3, Siyuan Cui4, Ruirong Xu4,5,6
1College of Integrated Traditional Chinese and Western Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250014, China.
Current medicinal chemistry
|January 11, 2024
概括
研究人员审查了FLT3抑制剂用于急性髓性白血病 (AML) 治疗. 诸如多目标和不可逆转的抑制剂等新策略是克服FLT3突变AML药物耐药性的关键.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 类似FMS的铁酶3 (FLT3) 突变在急性髓性白血病 (AML) 中很普遍.
- 一种受体氨酸激酶FLT3,调节了造血干细胞的增殖和分化.
- 用小分子抑制剂向FLT3是AML的关键治疗策略.
研究的目的:
- 总结FLT3抑制剂的结构特征和生物活性.
- 审查AMLFLT3抑制剂研究的最新进展.
- 确定FLT3向治疗中的挑战和未来研究方向.
主要方法:
- 使用PubMed和SciFinder®数据库进行文献审查.
- 从2014年到现在,对有关"FLT3抑制剂"和"急性髓性白血病"的出版物进行了集中调查.
- 排除专利文献,以专注于研究出版物.
主要成果:
- 代表性FLT3抑制剂的结构特征和生物作用的概述.
- 目前用于FLT3突变AML的FLT3抑制剂的概述.
- 讨论FLT3抑制剂开发和应用中遇到的挑战.
结论:
- 许多FLT3抑制剂可用于FLT3突变AML治疗.
- 查多目标FLT3抑制剂对于对抗耐药性至关重要.
- 不可逆转的FLT3抑制剂为开发新的治疗剂提供了新的途径.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K


